Stock Hero Advertisement SPDR Advertisement
Home > Boards > Stock Clubs > Short-Term > Make Me Wealthy FDA

AVII $ 1.54 AF from 2010

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Abubye Member Profile
Member Level 
Followed By 2
Posts 207
Boards Moderated 1
Alias Born 01/24/10
160x600 placeholder
Advertisement
Deutsche Bank on Sunday said its first-quarter net profit fell around 50% as strong revenue growth was outweighed by a record penalty to settle with authorities over rate-rigging allegations earlier this week.
More Top Equities Stories Of The Day
Comcast Spent Big For Little Result
Mylan Raises Bid for Generic Drug Maker Perrigo -- 6th Update
European Stocks Fall After Greek Talks Deadlock
Tech Giants Help Track Nepal Quake Survivors as Communications Hit
Nasdaq Composite, S&P 500 Close at New Highs
Strong iPhone Sales Will Power Apple's Encore
Asian Shares Rise, Mining Stocks Lift Sydney-- Update
ARM Holdings Chairman Stuart Chambers Buys 20,000 Shares
Abubye Member Level  Saturday, 03/31/12 03:57:23 PM
Re: Abubye post# 118
Post # of 125 
AVII $ 1.54 AF from 2010

AVI Biopharma(AVII) has a long and checkered history of biotech drug development futility, but the company's early work on a novel drug to correct the genetic damage in boys with Duchenne muscular dystrophy (DMD) is very interesting. The AVI drug, AVI-4658 is designed to "skip over" the section of damaged gene in DMD patients and therefore restore the gene's ability to produce partially functioning dystrophin, a protein that plays a key role in muscle function and repair. [The genetic inability to make dystrophin is what causes muscular dystrophy.]
Studies in a very small number of patients done in the U.K. have shown AVI-4658 to be relatively safe and even better, some of the patients showed a restoration of dystrophin levels. AVI is in the process of getting FDA sign off to begin clinical trials in the U.S. next year.
DMD is a rare genetic disorder, so AVI is working from the playbook successfully used by Genzyme(GENZ), BioMarin Pharmaceuticals(BMRN) and Alexion Pharmaceuticals(ALXN) -- develop a drug for a rare, genetic disorder with a sky-high price tag that patients will need to take for the rest of their lives. That's an excellent way to make investors happy, if the drug works.
I may be a bit late to the AVI story, unfortunately. The stock has almost doubled since April, trading today at just under $2 a share. Owing to its checkered past, AVI is saddled with more than 100 million shares outstanding and the company probably needs to raise cash at some point soon, but if '4658 is successful, AVI's share price today will look very cheap

http://www.thestreet.com/story/10861870/1/rodman-rambles-promising-biotechs.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist